EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

Ginette Santiago-Sanchez, Francesca Rosato, Kellsye P Fabian, Michelle R Padget, Jung-Min Lee, Fatima Karzai, Jeffrey Schlom, James L Gulley, Duane H Hamilton, Jonelle K Lee, Margaret R Pruitt, Andrew Bayliffe und 4 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Ginette Santiago-Sanchez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Receptors, Antigen, T-Cell, alpha-beta, Prostatic Neoplasms, Castration-Resistant, Piperazines. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural Research Program of the Center for Cancer Research, National Institutes of Health, Cooperative Research and Development Agreement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic castration-resistant prostate cancer (mCRPC) remains an aggressive disease with limited response to systemic therapies despite androgen deprivation. Immune-excluded prostate tumors are typically resistant to immunotherapy. STAR0602 is a selective bifunctional T-cell agonist composed of an antibody targeting Vβ6 and Vβ10 T-cell receptor chains fused to human interleukin-2 that selectively expands Vβ6 + CD8 + memory T cells and has demonstrated clinical activity as a monotherapy in anti-programmed death-ligand 1-resistant tumors ( NCT05592626 ). We hypothesized that combining poly ADP-ribose polymerase (PARP) inhibition with Vβ-directed T-cell activation would enhance antitumor immunity and promote polyclonal T-cell responses in immune-excluded prostate cancer.

Methods

The antitumor activity of the PARP inhibitor olaparib combined with mSTAR1302, the murine surrogate of STAR0602, was evaluated in TRAMP-C2 and RM-1 prostate tumor models. Tumor growth, survival, and immune responses were assessed by flow cytometry and functional depletion studies. The role of tumor-intrinsic TRAIL-R2 signaling was evaluated using a TRAIL-R2 knockout TRAMP-C2 model, and clinical relevance was explored by assessing TRAIL-R2 expression in tumor samples from patients treated with olaparib in a Phase 2 clinical trial ( NCT02484404 ).

Results

Combination therapy with olaparib and mSTAR1302 induced significant tumor regression and improved survival compared with either agent alone. Treatment increased tumor-infiltrating lymphocytes, expanded activated Vβ13 + CD4 + and Vβ13 + CD8 + T cells, reduced immunosuppressive populations, and enriched stem-like progenitor exhausted CD8 + T cells. Depletion studies demonstrated that Vβ13 + CD4 + T cells, Vβ13 + CD8 + T cells, natural killer cells, and interferon-γ were required for therapeutic efficacy. TRAIL-R2 knockout experiments demonstrated that tumor-intrinsic TRAIL-R2 signaling contributes to the antitumor activity of the combination. Mechanistically, these findings support a model in which PARP inhibition sensitizes tumors while mSTAR1302-mediated Vβ13 + T-cell expansion initiates a broader polyclonal antitumor immune response associated with antigen spreading and recognition of multiple tumor antigens and neoepitopes.

Conclusions

These findings suggest that combining tumor-sensitizing therapies with selective T-cell activation may represent a broader strategy to overcome immune exclusion in solid tumors. Together, these results provide mechanistic rationale for clinical evaluation of olaparib in combination with STAR0602 in patients with mCRPC who have progressed on androgen deprivation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsReceptors, Antigen, T-Cell, alpha-betaProstatic Neoplasms, Castration-ResistantPiperazinesPhthalazinesAnimalsMaleHumansMiceCell Line, Tumor

Stichwörter der Autor:innen

Combination therapyImmune modulatoryImmunotherapyProstate CancerT cell

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsReceptors, Antigen, T-Cell, alpha-betaolaparibPiperazinesPhthalazines

Autor:innen und Institutionen

  • Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Marengo Therapeutics, Boston, Massachusetts, USA.
  • Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA jh241d@nih.gov.

Förderung

  • Intramural Research Program of the Center for Cancer Research
  • National Institutes of Health
  • Cooperative Research and Development Agreement
  • CRADA-National Cancer Institute and Marengo Therapeutics

Zitieren

APA

Santiago-Sanchez, G., Rosato, F., Fabian, K. P., Padget, M. R., Lee, J. M., Karzai, F., Schlom, J., Gulley, J. L., Hamilton, D. H., Lee, J. K., Pruitt, M. R., Bayliffe, A., Su, Z., Moisan, J., Katragadda, M., & Hodge, J. W. (2026). PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014518

Vancouver

Santiago-Sanchez G, Rosato F, Fabian KP, Padget MR, Lee JM, Karzai F, et al. PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014518

BibTeX
@article{SantiagoSanchez2026,
  author = {Santiago-Sanchez, Ginette and Rosato, Francesca and Fabian, Kellsye P and Padget, Michelle R and Lee, Jung-Min and Karzai, Fatima and Schlom, Jeffrey and Gulley, James L and Hamilton, Duane H and Lee, Jonelle K and Pruitt, Margaret R and Bayliffe, Andrew and Su, Zhen and Moisan, Jacques and Katragadda, Madan and Hodge, James W},
  title = {PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014518}
}
Kostenlos starten →